Association of anti-GM1 antibodies but not of anti-cytomegalovirus, Campylobacter jejuni and Helicobacter pylori IgG, with a poor outcome in Guillain-Barré syndrome

Journal of the Neurological Sciences

Volumn 213, Issue 1-2, 2003, Pages 55-60

  Annunziata, Pasquale ^a   Figura, Natale ^a   Galli, Rosita ^a   Mugnaini, Floriano ^a   Lenzi, Cristina ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Autoimmunity; Campylobacter jejuni; Cytomegalovirus; Ganglioside; Guillain Barr syndrome; Helicobacter pylori; Polyneuropathy

Indexed keywords

BACTERIUM ANTIBODY; CYTOMEGALOVIRUS ANTIBODY; GANGLIOSIDE ANTIBODY;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; ASSAY; AUTOIMMUNITY; CAMPYLOBACTER JEJUNI; CLINICAL ARTICLE; CONTROLLED STUDY; CONVALESCENCE; CORRELATION ANALYSIS; DISABILITY; DISEASE ASSOCIATION; FEMALE; GUILLAIN BARRE SYNDROME; HELICOBACTER PYLORI; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; MALE; MICROORGANISM; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; STATISTICAL SIGNIFICANCE;

EID: 0038165790     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(03)00149-7     Document Type: Article

References (42)

1. Rees J.H., Soudain S.E., Gregson N.A., Hughes R.A.C. A prospective case-control study to investigate the relationship between Campylobacter jejuni infection and Guillain-Barré syndrome. New Engl. J. Med. 333:1995;1374-1379.
2. Winer J.B., Hughes R.A.C., Anderson M.J., Jones D.M., Kangro H., Watkins R.F.P. A prospective study of acute idiopathic neuropathy: II. Antecedent events. J. Neurol. Neurosurg. Psychiatry. 51:1988;613-618.
3. Dowling P.C., Cook S.D. Role of infection in Guillain-Barré syndrome: laboratory confirmation of Herpesviruses in 41 cases. Ann. Neurol. 9:1981;44-55. [suppl].
4. Goldschmidt B., Menonna J., Fortunato J., Dowling P., Cook S.D. Mycoplasma antibody in Guillain-Barré syndrome and other neurological disorders. Ann. Neurol. 7:1980;108-112.
5. Chiba S., Sugiyama T., Matsumoto H., Hisano K., Awakawa T., Hiura K.et al. Antibodies against Helicobacter pylori were detected in the cerebrospinal fluid obtained from patients with Guillain-Barré syndrome. Ann. Neurol. 44:1998;686-688.
6. Ilyas A.A., Mithen F.A., Dalakas M.C., Chen Z.-W., Cook S.D. Antibodies to acidic glycolipids in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J. Neurol. Sci. 107:1992;111-121.
7. Jacobs B.C., Van Doorn P.A., Schmitz P.I.M., Tio-Gillen A.P., Herbrink P., Visser L.H.et al. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome. Ann. Neurol. 40:1996;181-187.
8. Ho T.W., Willison H.J., Nachamkin I., Li C.Y., Veitch J., Ung H.et al. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome. Ann. Neurol. 45:1999;168-173.
9. Hao Q., Saida T., Kuroki S., Nishimura M., Nukina M., Obayashi H.et al. Antibodies to gangliosides and galactocerebroside in patients with Guillain-Barré syndrome with preceding Campylobacter jejuni and other identified infections. J. Neuroimmunol. 81:1998;116-126.
10. Oomes P.G., Jacobs B.C., Hazenberg M.P.H., Banffer J.R.J., Van der Meché F.G.A. Anti-GM1 IgG antibodies and Campylobacter jejuni bacteria in Guillain-Barré syndrome: evidence of molecular mimicry. Ann. Neurol. 38:1995;170-175.
11. Rees J.H., Gregson N.A., Hughes R.C.A. Anti-ganglioside GM1 antibodies in Guillain-Barré syndrome and their relationship to Campylobacter jejuni infection. Ann. Neurol. 38:1995;809-816.
12. Ho T.W., Mishu B., Lui C.Y., Gao C.Y., Cornblath D.R., Griffin J.W.et al. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 118:1995;597-605.
13. Jacobs B.C., Rothbarth P.H., Van der Meché F.G.A., Herbrink P., Schmitz P.I.M., de Klerk M.A.et al. The spectrum of antecedent infections in Guillain-Barré syndrome. A case-control study. Neurology. 51:1998;1110-1115.
14. Yuki N., Yoshino H., Sato S., Miyatake T. Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology. 40:1990;1900-1902.
15. Van den Berg L.H., Marrink J., De Jager A.E.J., de Jong H.J., van Imhoff G.W., Latov N.et al. Anti-GM1 antibodies in patients with Guillain-Barré syndrome. J. Neurol. Neurosurg. Psychiatry. 55:1992;8-11.
16. Visser L.H., Van der Mechè F.G.A., Meulstee J., Rothbarth P.Ph., Jacobs B.C., Schmitz P.I.M.et al. Cytomegalovirus infection and Guillain-Barré syndrome: the clinical, electrophysiologic, and prognostic features. Neurology. 47:1996;668-673.
17. Hadden R.D.M., Karch H., Hartung H.P., Zielasek J., Weissbrich B., Schubert J.et al. Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology. 56:2001;758-765.
18. Asbury A.K., Cornblath D.R. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann. Neurol. 27:1990;S21-S24. [suppl].
19. Hughes R.A.C., Newsom-Davis J.M., Perkin G.D., Pierce J.M. Controlled trial of prednisolone in acute polyneuropathy. Lancet. ii:1978;750-753.
20. Simone I.L., Annunziata P., Maimone D., Liguori M., Leante R., Livrea P. Serum and CSF anti-GM1 antibodies in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J. Neurol. Sci. 114:1993;49-55.
21. Figura N., Oderda G., Verdiani S. Evaluation of a commercial ELISA kit for the serological diagnosis of Helicobacter pylori infection. Microbiologica. 17:1994;319-325.
22. Boucquey D., Sindic C.J.M., Lamy M., Delmée M., Tomasi J.P., Laterre E.C. Clinical and serological studies in a series of 45 patients with Guillain-Barré syndrome. J. Neurol. Sci. 104:1991;56-63.
23. De Mattia D., Stroffolini T., Arista S., Pistoia D., Giammanco A., Maggio M.et al. Prevalence of cytomegalovirus infection in Italy. Epidemiol. Infect. 107:1991;421-427.
24. Jacobs B.C., van Doorn P.A., Groeneveld J.H., Tio-Gillen A.P., van der Meché F.G. Cytomegalovirus infections and anti-GM2 antibodies in Guillain-Barré syndrome. J. Neurol. Neurosurg. Psychiatry. 62:1997;641-643.
25. Khalili-Shirazi A., Gregson N., Gray I., Rees J., Winer J., Hughes R. Antiganglioside antibodies in Guillain-Barré syndrome after a recent cytomegalovirus infection. J. Neurol. Neurosurg. Psychiatry. 66:1999;376-379.
26. Hughes R.A.C., Rees J.H. Clinical and epidemiological features of Guillain-Barré syndrome. J. Infect. Dis. 176:1997;S92-S98.
27. Guarino M., Casmiro M., D'Alessandro R. Campylobacter jejuni infection and Guillain-Barré syndrome: case-control study. Emilia-Romagna study group on clinical epidemiological problems in neurology. Neuroepidemiology. 17:1998;296-302.
28. Nevo Y., Pestronk A. Acute immune polyneuropathies: correlations of serum antibodies to Campylobacter jejuni and Helicobacter pylori with anti-GM1 antibodies and clinical pattern of disease. J. Infect. Dis. 176(Suppl. 2):1997;S154-S156.
29. Sack D.A., Lastovica A.J., Chang S.H., Pazzaglia G. Microtiter assay for detecting Campylobacter spp. and Helicobacter pylori with surface gangliosides which bind cholera toxin. J. Clin. Microbiol. 36:1998;2043-2045.
30. Figura N., Palazzuoli A., Faglia S., Lenzi C., Borrello F., Palazzuoli V.et al. Infection by CagA-positive Helicobacter pylori strains in patients with ischemic heart disease. Prevalence and association with exercise-induced electrocardiographic abnormalities. Dig. Dis. Sci. 47:2002;831-836.
31. Gregson N.A., Koblar S., Hughes R.A. Antibodies to gangliosides in Guillain-Barré syndrome: specificity and relationship to clinical features. Q. J. Med. 86:1993;111-117.
32. Enders U., Karch H., Toyka K.V., Michels M., Zielasek J., Pette M.et al. The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barré syndrome and in other neuroimmunological disorders. Ann. Neurol. 34:1993;136-144.
33. Vriesendorp F.J., Mishu B., Blaser M.J., Koski C.L. Serum antibodies to GM1, GD1b, peripheral nerve myelin, and Campylobacter jejuni in patients with Guillain-Barré syndrome and controls: correlation and prognosis. Ann. Neurol. 34:1993;130-135.
34. Kuwabara S., Asahina M., Koga M., Mori M., Yuki N., Hattori T. Two patterns of clinical recovery in Guillain-Barré syndrome with IgG anti-GM1 antibody. Neurology. 51:1998;1656-1660.
35. Thomas F.P., Lee A.M., Romas S.N., Latov N., Hays P. Monoclonal IgMs with anti-Gal(beta1-3)GalNAc activity in lower motor neuron disease: identification of glycoprotein antigens in neural tissue and cross-reactivity with serum immunoglobulins. J. Neuroimmunol. 23:1989;167-174.
36. Thomas F.P., Trojaborg W., Nagy C., Santoro M., Sandiq S.A., Latov N.et al. Experimental autoimmune neuropathy with anti-GM1 antibodies and immunoglobulin deposits at the nodes of Ranvier. Acta Neuropathol. 82:1991;378-383.
37. Santoro M., Uncini A., Corbo M., Staugaitis S.M., Thomas F.P., Hays A.P.et al. Experimental conduction block induced by serum from a patient with anti-GM1 antibodies. Ann. Neurol. 31:1992;385-390.
38. Takigawa T., Yasuda H., Kikkawa R., Shigeta Y., Saida T., Kitasato H. Antibodies against GM1 ganglioside affect K+ and Na+ currents in isolated rat myelinated nerve fibers. Ann. Neurol. 37:1995;436-442.
39. Harvey G.K., Toyka K.V., Zielasek J., Kiefer R., Simonis C., Hartung H.-P. Failure of anti-GM1 IgG or IgM to induce conduction block following intraneural transfer. Muscle Nerve. 18:1995;388-394.
40. Hirota N., Kaji R., Bostock H., Shindo K., Kawasaki T., Mizutani K.et al. The physiological effect of anti-GM1 antibodies on saltatory conduction and transmembrane currents in single motor axons. Brain. 120:1997;2159-2169.
41. Buchwald B., Toyka K.V., Zielasek J., Weishaupr A., Schweiger S., Dudel J. Neuromuscular blockade by IgG antibodies from patients with Guillain-Barré syndrome: a macro-patch-clamp study. Ann. Neurol. 44:1998;913-922.
42. Yuki N., Yamada M., Koga M., Odaka M., Susuki K., Tagawa Y.et al. Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside. Ann. Neurol. 49:2001;712-720.